Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T17:17:49.342Z.
Calculation as of: 2026-10-06T17:17:49.342Z.
Quote observation: 2026-10-06T17:11:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d2e468d5d1fee912cc594a855ce64a44190db3c5d14d549897f680d6209c50fe
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2023-05-15.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
EBITDA YIELD AVG TTM
N/A
EBITDA YIELD AVG 3Y
N/A
EBITDA YIELD AVG 5Y
N/A
EBITDA YIELD AVG 10Y
N/A
EBITDA YIELD AVG 15Y
N/A
EBITDA YIELD AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Precision Optics Corporation, Inc.
Market Cap
$48.27M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$49.14M
EBITDA Yield
N/A
TTM Avg
11.25%
3Y Avg
14.93%
5Y Avg
13.84%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Precision Optics Corporation, Inc. (POCI) | $48.27M | N/A | N/A | N/A | N/A |
| Lite Strategy, Inc. (LITS)vs › | $48.49M | N/A | N/A | N/A | N/A |
| TELA Bio, Inc. (TELA)vs › | $49.21M | N/A | N/A | N/A | N/A |
| Sensus Healthcare, Inc. (SRTS)vs › | $49.14M | N/A | 11.25% | 14.93% | 13.84% |
| Instil Bio, Inc. (TIL)vs › | $46.97M | N/A | N/A | N/A | N/A |
| Microbot Medical Inc. (MBOT)vs › | $49.67M | N/A | 0.89% | 5.54% | 4.70% |
| Apollomics, Inc. (APLM)vs › | $49.96M | N/A | N/A | N/A | N/A |
| Celularity Inc. (CELU)vs › | $50.08M | N/A | N/A | N/A | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $50.45M | N/A | N/A | N/A | N/A |
| INmune Bio, Inc. (INMB)vs › | $49.47M | N/A | 3.11% | 2.71% | 2.71% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA YIELD |
|---|---|
| 2023-05-15 | 0.84% |
| 2023-05-12 | 0.90% |
| 2023-05-11 | 0.89% |
| 2023-05-10 | 0.88% |
| 2023-05-09 | 0.90% |
| 2023-05-08 | 0.90% |
| 2023-05-05 | 0.86% |
| 2023-05-04 | 0.89% |
| 2023-05-03 | 0.88% |
| 2023-05-02 | 0.89% |
| 2023-05-01 | 0.88% |
| 2023-04-28 | 0.87% |
| 2023-04-27 | 0.86% |
| 2023-04-26 | 0.87% |
| 2023-04-25 | 0.86% |
| 2023-04-24 | 0.86% |
| 2023-04-21 | 0.86% |
| 2023-04-20 | 0.84% |
| 2023-04-19 | 0.84% |
| 2023-04-18 | 0.84% |
| 2023-04-17 | 0.83% |
| 2023-04-14 | 0.84% |
| 2023-04-13 | 0.87% |
| 2023-04-12 | 0.88% |
| 2023-04-11 | 0.83% |
| 2023-04-10 | 0.83% |
| 2023-04-06 | 0.82% |
| 2023-04-05 | 0.81% |
| 2023-04-04 | 0.86% |
| 2023-04-03 | 0.86% |
| 2023-03-31 | 0.81% |
| 2023-03-30 | 0.86% |
| 2023-03-29 | 0.85% |
| 2023-03-28 | 0.90% |
| 2023-03-27 | 0.91% |
| 2023-03-24 | 0.91% |
| 2023-03-23 | 0.90% |
| 2023-03-22 | 0.90% |
| 2023-03-21 | 0.90% |
| 2023-03-20 | 0.90% |
| 2023-03-17 | 0.93% |
| 2023-03-16 | 0.82% |
| 2023-03-15 | 0.83% |
| 2023-03-14 | 0.77% |
| 2023-03-13 | 0.82% |
| 2023-03-10 | 0.84% |
| 2023-03-09 | 0.81% |
| 2023-03-08 | 0.77% |
| 2023-03-07 | 0.77% |
| 2023-03-06 | 0.77% |
| 2023-03-03 | 0.77% |
| 2023-03-02 | 0.77% |
| 2023-03-01 | 0.78% |
| 2023-02-28 | 0.78% |
| 2023-02-27 | 0.78% |
| 2023-02-24 | 0.79% |
| 2023-02-23 | 0.79% |
| 2023-02-22 | 0.79% |
| 2023-02-21 | 0.79% |
| 2023-02-17 | 0.79% |
| 2023-02-16 | 0.79% |
| 2023-02-15 | 0.79% |
